Research programme: arrhythmia therapeutics - MerckAlternative Names: DPO-1
Latest Information Update: 31 Mar 2010
At a glance
- Originator Merck & Co
- Mechanism of Action Potassium channel modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Arrhythmias
Most Recent Events
- 15 Dec 2009 Preclinical development is ongoing in USA
- 05 Sep 2007 Data presented at the 234th American Chemistry Society National Meeting (234th-ACS-2007) added to the pharmacokinetics and Arrhythmias pharmacodynamics section
- 02 Aug 2006 A preclinical study has been added to the pharmacokinetics section